Colorectal cancer (CRC) is the second leading cause of cancer deaths in the United States. Although routine endoscopic screening and early surgical intervention has reduced the incidence of CRC mortality, the five-year survival rate of patients with advanced disease is less than 10%. Genomic studies have suggested key genes that drive CRC initiation and progression but this information has yet to produce effective new therapies, in part, because current models to validate cancer drivers and new therapeutic targets in CRC are slow and cumbersome. This proposal aims to develop and utilize new murine models of colorectal cancer (CRC) to define genetic requirements for cancer progression and therapy response. To this end, we implement a novel approach to validate cancer drivers and therapeutic targets using orthotopic colon stem cell transplants that form focal colon tumors and progress to malignant disease. This circumvents the problems associated with transgenic mouse models, which i) rarely develop colon tumors and ii) do not live long enough to develop metastases due to small intestinal tumor burden. We have previously developed a robust model of APC loss in the colon using short hairpin RNAs targeting APC and showed that APC loss is required for disease maintenance of the primary tumor (14). My plan focuses on two future directions from that study: i) to test if Apc restoration in later CRC stages (Stage II, III, or IV will result in disease regression, and ii) to test if Smad4 mutations abrogate the dependence on hyperactive WNT signaling conferred by Apc loss in CRC. Successful completion of the project will produce new CRC models, validate potential cancer drivers, and identify key determinants that influence the action of WNT pathway inhibitors.

Public Health Relevance

Colorectal cancer (CRC) is a major cause of cancer related deaths due to the lack of therapies available to patients who present with metastatic disease. Therefore, there is a need for a preclinical system to study advanced CRC disease in mammalian models that account for the complex environment in which these cancer cells grow. Such a model could be used to develop new therapies, as well as predict patient responses to treatment.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Individual Predoctoral NRSA for M.D./Ph.D. Fellowships (ADAMHA) (F30)
Project #
5F30CA200110-03
Application #
9476950
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Damico, Mark W
Project Start
2016-05-10
Project End
2020-05-09
Budget Start
2018-05-10
Budget End
2019-05-09
Support Year
3
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Weill Medical College of Cornell University
Department
Administration
Type
Schools of Medicine
DUNS #
060217502
City
New York
State
NY
Country
United States
Zip Code
10065
Vittoria, Marc A; Shenk, Elizabeth M; O'Rourke, Kevin P et al. (2018) A genome-wide microRNA screen identifies regulators of tetraploid cell proliferation. Mol Biol Cell 29:1682-1692
O'Rourke, Kevin P; Loizou, Evangelia; Livshits, Geulah et al. (2017) Transplantation of engineered organoids enables rapid generation of metastatic mouse models of colorectal cancer. Nat Biotechnol 35:577-582
O'Rourke, Kevin P; Dow, Lukas E; Lowe, Scott W (2016) Immunofluorescent Staining of Mouse Intestinal Stem Cells. Bio Protoc 6:
O'Rourke, Kevin P; Ackerman, Sarah; Dow, Lukas E et al. (2016) Isolation, Culture, and Maintenance of Mouse Intestinal Stem Cells. Bio Protoc 6:
Dow, Lukas E; O'Rourke, Kevin P; Simon, Janelle et al. (2015) Apc Restoration Promotes Cellular Differentiation and Reestablishes Crypt Homeostasis in Colorectal Cancer. Cell 161:1539-1552